| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440948 | European Journal of Cancer | 2016 | 10 Pages |
Abstract
Postneoadjuvant treatment with zoledronate does not improve outcome in patients without pathological complete response after neoadjuvant anthracycline-taxane-based chemotherapy for early breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
G. von Minckwitz, M. Rezai, H. Tesch, J. Huober, B. Gerber, D.M. Zahm, J. Hilfrich, S.D. Costa, P. Dubsky, J.U. Blohmer, C. Denkert, C. Hanusch, C. Jackisch, S. Kümmel, P.A. Fasching, A. Schneeweiss, S. Paepke, M. Untch, S. Loibl,